The World Health Organization (WHO) has endorsed that cannabidiol (CBD) should not be classified as a scheduled drug by the United Nations. Last month, the WHO Expert Committee on Drug Dependence (ECDD held a meeting in Geneva, Switzerland for the discussion of the possible dangers of seventeen different drug substances, which included cannabidiol.
When it came time to review CBD’s, evidence from both human and animal studies were considered and it revealed that CBD’s could have medicinal value in treating epilepsy. It was also revealed that CBD treatment has minimal potential for abuse and/or dependence.
Because of this, the ECDD “concluded that current information does not justify scheduling of cannabidiol.” The group will conduct a more comprehensive study of cannabis and cannabinoids this upcoming May.
Raúl Elizalde, the president of a Mexican medical marijuana company HempMeds, was a speaker at the November convention. He pleaded to the committee not to classify CBD as a scheduled drug and urged for them to grant access for its usage as a dietary supplement. Elizalde fights hard for medical marijuana as the issue remains close to his heart. Elizalde became a marijuana activist to fight for medical marijuana treatments for his daughter, who suffers from a harsh form of epilepsy.
“We’re ecstatic that these international health leaders agree that CBD is a substance that should not be scheduled and has therapeutic value for a variety of medical conditions. We look forward to continuing our conversation about CBD’s many benefits in 2018,” said Elizalde after find out about the organizations decision.
The effects of this decision can cause a ripple effect around the globe. A ruling by the U.N. that CBD should no longer be regulated could result in its rescheduling under the Controlled Substances Act in the United States as well, where CBD is listed as a Schedule 1 narcotic.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
